Microbes in Your Mouth May Impact Your Risk of Cognitive Decline
In a study of 55 participants with mild cognitive impairment (MCI), those who hosted a relatively high abundance of bacteria from the genus Neisseria in their mouths had better working memory, executive function, and visual attention.
Even among 60 people without cognitive decline, when Neisseria dominated the oral microbiome, working memory scores improved.
The current study, led by researchers at the University of Exeter in the UK, suggests that by promoting certain bacteria in the mouth we could potentially delay cognitive decline. This could be achieved with probiotics or prebiotics that can boost and feed certain microbial communities in the oral cavity within just weeks.
The findings align with other recent studies, which suggest the cause of dementia may be coming from inside the mouth.
In recent years, for instance, poor oral health has emerged as a major risk factor for cognitive decline. Scientists have even found some bacteria linked to gum disease in the brains of those who have died from Alzheimer's.
Still, not all microbes in the mouth are necessarily harmful to the brain; some could be protective, too. Similar to bacteria in the gut, a nicely balanced microbiome is key.
The Neisseria genus includes more than 20 species of bacteria, many of which typically live in the nose and mouth quite peacefully and may even confer health benefits.
Recently, studies have found Neisseria bacteria can lower a person's systemic blood pressure by helping to convert nitrate-rich foods (usually vegetables) to nitric oxide.
Nitric oxide is a key signaling molecule in the body, which protects against gum disease and helps control and regulate blood pressure, as well as our cardiovascular response to exercise. It could also help keep the brain healthy.
Based on recent evidence, some neuroscientists suspect nitric oxide may protect the central nervous system by boosting neural plasticity and improving the efficiency and power of neural messages. The signaling molecule may even reduce neural inflammation – a central mechanism of Alzheimer's.
Intriguingly, people who are genetically predisposed to Alzheimer's tend to have trouble naturally producing nitric oxide.
In the current study, molecular biologist Joanna L'Heureux and her colleagues found that of 33 participants with MCI who were genetically predisposed to Alzheimer's, many had oral microbiomes dominated by the Prevotella genus and not the Neisseria genus.
One species of Prevotella in particular, P. intermedia, was a predictor for an elevated genetic risk for dementia. This suggests it could be used as an early marker of disease risk.
In the study, when the Prevotella genus reigned, there was less nitrate available in the mouth to convert to nitric oxide, probably because Prevotella uses the nitrate for other means.
Thus, by promoting Neisseria and eradicating Prevotella in the mouth, the authors of the study think they could potentially influence nitric oxide availability, thereby influencing the health of the brain.
Nitrate-rich diets, like the Mediterranean diet, are linked to improved brain health, but further research is needed to understand the link between what we put in our mouths, our oral microbiome, and the major signaling molecules produced by those microbes.
A 2021 study in healthy older people, for instance, found a correlation between oral microbiomes dominated by Neisseria (and a co-occurring genus, called Haemophilus) and sustained attention, even when the amount of dietary nitrate changed.
Other research has linked higher rates of Neisseria to younger age, lower body mass index, fewer teeth with damage, and not smoking.
"Collectively, these results indicate that a high relative abundance of bacteria belonging in the Neisseria–Haemophilus module is associated with better cognitive outcomes in individuals with MCI as well as in healthy older people," conclude L'Heureux and her team.
The study was published in PNAS Nexus.
Tuberculosis Outbreak in Kansas Is Among Largest on Record in US
Scientists Confirm a New Strain of Bird Flu Has Emerged in The US
Exercise Doesn't Burn as Many Calories as You Think, Experts Say
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
Hyperfine Swoop® AI-Powered Portable MRI System Showcased in Clinical Studies Designed to Broaden Access to Dementia Care
GUILFORD, Conn.--(BUSINESS WIRE)-- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced two significant advancements highlighting the potential of its innovative MRI technology to expand dementia screening, enhance monitoring, and improve care. A new study conducted by the University of Kansas Alzheimer's Disease Research Center is exploring the use of the next-generation Swoop® system to expedite dementia diagnosis in a memory clinic. Globally, over 57 million people live with dementia, with Alzheimer's disease accounting for 60–80% of cases (Centers for Disease Control, World Health Organization). Limited access to conventional MRI, particularly in underserved and rural areas, often delays diagnosis and treatment. The Swoop® system addresses these barriers by delivering portable, accessible brain imaging in outpatient settings, including neurology clinics and infusion centers. A new study conducted by the University of Kansas Alzheimer's Disease Research Center is exploring the use of the next-generation Swoop® system to expedite dementia diagnosis in a memory clinic. Led by Dr. Jeffrey Burns, the Accelerated Clinical Evaluations for Alzheimer's Disease (ACE-AD) pioneers an innovative approach that combines in-office MR imaging, cognitive testing, and blood biomarkers into a single nurse-led clinic visit, aimed to improve patient care and ease healthcare system burdens. Dr. Burns highlights the importance of accessibility, stating, "The shortage of cognitive specialists limits our ability to meet growing demand for dementia care. Tools like the Swoop® system could enable scalable, timely diagnoses and earlier treatment, particularly for patients in rural and underserved areas." Additionally, two poster presentations from researchers in the Benzinger Lab at Washington University School of Medicine in St. Louis will be presented at this year's Alzheimer's Association International Conference, including interim results from the CARE PMR study, which evaluates the use of the Swoop® system for ARIA-E monitoring. Title: The Use of Portable MRI in the Detection and Monitoring of Amyloid-Related Imaging Abnormalities Authors: J. Hu, K. Sharifi, H. Alkelani, et al. Title: Assessing Low-field MRI Volumetric and White Matter Hyperintensity Lesion Measures using WMH-SynthSeg Authors: H. Shimony, S. Keefe, H. Alkelani, et al. 'These studies underscore how the Swoop® system is transforming brain imaging by bringing MRI to serve patients and clinicians across brain conditions where MRI access can significantly improve care,' said Maria Sainz, President and CEO of Hyperfine, Inc. 'Neurodegenerative conditions represent immense clinical and economic burdens for patients, caregivers, and health systems globally. The work that leading clinicians are doing with the Swoop® system in dementia screening and Alzheimer's drug therapy monitoring sets the stage for very large expansion opportunities for Hyperfine.' For more information about the Swoop® system, please visit Centers for Disease Control and Prevention. About Alzheimer's. Alzheimer's Disease & Dementia. Updated August 15, 2024. Accessed July 22, 2025. ‑dementia/about/ World Health Organization. Dementia. World Health Organization News‑Room Fact Sheets. Published March 31, 2025. Accessed July 22, 2025. About the Swoop® Portable MRI Systems The Swoop® Portable MR Imaging® Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. About Hyperfine, Inc. Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine, Inc. Forward-Looking Statements This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the 'Company') may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'continue,' and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's goals and commercial plans, the benefits of the Company's products and services, and the Company's future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company's product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on the Nasdaq; the Company's inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in Company's filings with the Securities and Exchange Commission, including those under 'Risk Factors' therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Yahoo
14 hours ago
- Yahoo
Retired banker hits halfway mark in bid to run 200 marathons around coast
A retired banker who is striving to become the first man over the age of 60 to run the entire coastline of mainland Britain completed his 100th consecutive day of running. Steve James, 65, has reached the halfway point of his goal to run 200 marathons in 200 days, while researchers at the University of Exeter monitor the impact on his body. Mr James set off from Topsham, Devon on April 16 and will end his feat there after running anticlockwise around the coast for seven months. He currently runs for around six hours each day, occasionally staying with his wife in their camper van, or in various accommodation. 'Reaching the halfway stage is a milestone I could only have dreamed of when I set off 100 days ago,' he said as he marked the milestone by running from Oban to Craobh Haven . 'There have been points where I didn't know if I'd make it, but I've proved to myself I'm capable of pushing beyond my limits, both physical and mental. 'It's overwhelming looking back on what I've achieved. 'I feel so proud of myself and hope I can inspire others over 60, that you are never too old to attempt the impossible no matter how ridiculous it seems.' Mr James, a father of five, has already faced his share of hardships on his journey, running through harsh weather conditions, closed footpaths, severely blistered feet, and a gout flare-up resulting in a trip to hospital. The Exeter research team assessed him before his departure and continue to monitor him throughout this challenge. They are studying his calorie intake, blood, oxygen and muscle measurements to examine the effect of such an extreme sport on the body. 'By the end of this challenge, the scientists will have more insight into how far a 65-year-old person can push their body,' Mr James, who lives and trains on Dartmoor, said. 'Of all the challenges I've done, this is the most extreme and the biggest stretch.' At this stage the team has seen no adverse effects of this high-endurance challenge in the blood samples which are being used to measure hormone fluctuations, inflammation and overall health. Mr James has lost weight although this was a likely result the researchers anticipated because of his extreme calorie output. Dr Freyja Haigh, nutritional physiology researcher at the University of Exeter, said: 'Having reached this point would be an incredible achievement for anyone, but doing it in your 60s is a whole different ballgame. 'What Steve is doing really challenges the stereotypes of ageing and redefines what's possible later in life. 'It's also fascinating in terms of the science; Steve gives us a real insight into how this type of endurance affects the body of an older person. 'It's been such a privilege to work with him so far and I can't wait to see how he gets on in this next stage. 'We're currently tracking Steve's energy intake and expenditure in order to assess any changes in body mass, which is to be expected with this very physical challenge. 'We're unsure at the moment if Steve's weight loss is from fat or muscle mass. I'm hoping to visit him in the near future to take muscle thickness measurements at multiple points on the body to compare with those we took before he left.' Throughout his life, Mr James has loved physical challenges, from taking part in Ten Tors hiking challenge while at school, to cycling around the world in 220 days in 2019. The record for running the British coastline is held by Nick Butter, who completed the feat in 128 days at the age of 31. But Mr James is the first person over 60 to attempt the feat.
21 hours ago
What to know about Parkinson's disease following Ozzy Osbourne's death
Ozzy Osbourne, lead singer of the legendary heavy metal rock band Black Sabbath, died this week at age 76. Although Osbourne's cause of death hasn't yet been publicly released, he revealed in an exclusive interview with " Good Morning America" in 2020 that he had been diagnosed with Parkinson's disease in February of the previous year. "There's so many different types of Parkinson's. It's not a death sentence by any stretch of the imagination but it does affect certain nerves in your body," Osbourne's wife, Sharon, said during the interview. "And it's like you have a good day, a good day, and then a really bad day." Here's what you need to know about Parkinson's, including what are the symptoms, how it's diagnosed and what treatments are available. What is Parkinson's disease? Parkinson's is a neurodegenerative disorder characterized by the weakening of nerve cells, which become damaged and die, according to the National Institute of Neurological Disorders and Stroke (NINDS). The most significant loss of neurons occurs in an area near the base of the brain called the substantia nigra, NINDS said. The neurons in the substantia nigra produce dopamine, which is a neurotransmitter that plays a vital role in controlling movement. "As we grow older, all of us lose dopamine but the people who develop Parkinson's disease lose it faster," Dr. Osama Abu-Hadid, a neurologist specializing in movement disorders at New Jersey's Hackensack Meridian Neuroscience Institute at Hackensack University Medical Center, told ABC News. Parkinson's affects more than 1.1 million people in the U.S., according to the Parkinson's Foundation. That figure is expected to reach 1.2 million by 2030. "Generally, neurodegenerative diseases such as Alzheimer's and Parkinson's disease have been on the increase because people are living longer," Abu-Hadid said. There currently are no specific tests to diagnose Parkinson's disease. The diagnosis is clinical based on a physician's review of a patient's medical history and by performing a physical examination. What are the symptoms of Parkinson's disease? Progression of Parkinson's disease symptoms typically occurs slowly over several years and can vary from person to person, according to the Parkinson's Foundation. Typically, symptoms begin on one side of the body. While Parkinson's will eventually affect both sides of the body, one side will generally exhibit more severe symptoms than the other, according to NINDS. Symptoms of Parkinson's can include tremors, muscle stiffness, slowing of spontaneous movement, and problems with gait and balance. Patients may also experience difficulty chewing and swallowing or changes in speech. Some patients can also develop non-motor symptoms, including constipation, hallucinations, depression, loss of smell and sleep problems, Abu-Hadid said. What Parkinson's disease treatments are available? Currently, there is no cure for Parkinson's, but physical therapy can help slow progression of the disease and a healthy diet can promote overall well-being, according to Abu-Hadid. However, there are medications that may improve some Parkinson's symptoms. These include drugs that increase the level of dopamine in the brain, drugs that interact with other neurotransmitters to help ease some symptoms, and medications that can help control the non-motor symptoms, according to NINDS. If medications aren't working, "procedural options include deep brain stimulation, which is an electrode, or electrodes, that are placed in the brain by a neurosurgeon, and then a physician like myself programs the electrodes to give electricity in a certain way," Abu-Hadid said. The electrodes can stimulate the brain and help block signals that cause the motor symptoms of Parkinson's, according to NINDS.
